Welcome to our dedicated page for Im Cannabis SEC filings (Ticker: IMCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp. amended certain common share purchase warrants issued in its 2024 private placement by reducing the exercise price from C$4.32 to C$3.43 and extending the expiration date from November 12, 2026 to July 31, 2030. The warrants were originally exercisable upon issuance and, except for the exercise price and expiration, all other terms remain unchanged.
The amendments increase the timeframe and the lower threshold at which warrant holders may convert into common shares, which could raise the likelihood of exercise and therefore the potential for dilution if exercised. The Form of Warrant, the Form of Amendment and a press release are included as exhibits and the report is incorporated by reference into the company’s Form F-3 registration statements.
IM Cannabis Corp. submitted a Form 6-K reporting for the month of August 2025 and furnished several attachments dated August 12, 2025. The report includes a news release, interim consolidated financial statements for the three- and six-month periods ended June 30, 2025, a management's discussion and analysis (MD&A) for those periods, and CEO and CFO certifications of the interim filings. The form is signed by Oren Shuster as Chief Executive Officer and Director. The company indicates it files annual reports on Form 20-F.
IM Cannabis Corp. (IMCC) filed a Form 6-K announcing a new debt financing and a board change. On 6 July 2025 the company signed a Loan Agreement with L.I.A. Pure Capital Ltd. for up to US$2 million. The company has already received the first tranche of US$1 million; a second tranche of US$1 million may be drawn within 60 days, contingent on unspecified conditions.
The agreement grants the lender a right to recommend one director to the board. Pursuant to this right, Mr. Oz Adler, CPA, was appointed to IMCC’s board effective 6 July 2025. Adler is currently CEO and CFO of SciSparc Ltd. and sits on the boards of several Nasdaq-listed companies, bringing managerial, accounting and capital-markets experience.
The Loan Agreement (Exhibit 10.1) and a related press release dated 9 July 2025 (Exhibit 99.1) are furnished with the filing. Except for two specified paragraphs of the press release, the entire 6-K is incorporated by reference into IMCC’s Form F-3 registration statement (File No. 333-288346).
Key takeaways for investors:
- Immediate liquidity boost of US$1 million with potential for an additional US$1 million.
- New debt introduces repayment obligations not yet disclosed in the filing.
- Lender’s nomination right and Adler’s appointment modestly alter board composition.
IM Cannabis Corp. (Nasdaq: IMCC) has filed a Form F-3 shelf registration allowing it to issue up to $50 million in securities, including common shares, warrants or units combining the two. The filing provides the company with flexibility to raise capital "from time to time" through direct sales, agents, underwriters or dealers, as detailed in the forthcoming prospectus supplements.
The company’s non-affiliate market capitalization was approximately $15.9 million on 26 June 2025, based on 4,044,812 outstanding shares at a May 30 closing price of $6.20. The most recent Nasdaq trading price (25 June 2025) was $2.77 per share. IM Cannabis qualifies as both an emerging growth company (EGC) under the JOBS Act and a foreign private issuer, permitting streamlined disclosure obligations.
The registration statement invokes Rule 415, confirming that the securities may be issued on a continuous or delayed basis. The company has not sold securities under General Instruction I.B.5 in the previous 12 months. Risk disclosures, pricing, fees and use-of-proceeds will be provided in each prospectus supplement, and any related free-writing prospectus may update or modify the base document.
Proceeds are expected to support corporate purposes yet to be specified; investors are cautioned to review the "Risk Factors" section (page 4) once available. No securities may be sold until the SEC declares the shelf effective, and offers are limited to jurisdictions where lawful.